This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer is suing Metsera and Novo Nordisk, escalating a high-profile battle between two large pharmaceutical companies over the rights to an emerging obesity drug developer. In a statement Friday, Pfizer said it has initiated legal proceedings against Metsera, its board and Novo in Delaware Court of Chancery. The suit alleges that Novo’s bid, and Metsera’s beli ...